Dulux owner blocked from buying Plascon in SA

Loading player...
The Competition Commission has blocked a deal whereby AkzoNobel, the Dutch group that owns the paint brand Dulux, wanted to buy the owner of its local rival, Plascon, in South Africa.

Japanese-controlled Kansai Plascon Africa owns Plascon.
On Wednesday, the commission said that the proposed deal would result in a substantial lessening of competition in the market for the manufacturing and supply of paint.
"This is because the proposed merger combines the largest and second-largest manufacturers of decorative coatings who manufacture the well-known Plascon- and Dulux-branded paint products to create a dominant firm with a considerable market share."

The commission said that the companies are close competitors in terms of price, quality, and product range, and the merger would remove competitive rivalry, "thus reducing consumer choice".

In addition, the companies have both the ability and incentives to foreclose some of their competitors’ access to paint colourants, the commission found.

The companies did not suggest solutions to address the anti-competitive effect of the merger adequately, the commission added.
9 Nov 2022 1PM English South Africa Business News · Investing

Other recent episodes

BofA Slashes SA Growth Forecast as Inflation Surges

Bank of America has cut South Africa’s 2026 GDP growth forecast to 1.3%, warning that higher oil and fertilizer prices will keep inflation above 4% for most of the year. Economist Tatonga Rusike explains
23 Apr 3PM 11 min

Understanding SA’s First Wealth Score

Franc unveils South Africa’s first-ever Wealth Score, revealing that financial habits—not income—are the strongest predictor of financial health. We unpack why SA’s national score is 45/100 and the behavior gap between knowing and doing with Dr. Thomas Brennan, founder and CEO of Franc.
23 Apr 3PM 13 min

Clicks Lifts HEPS 8% Despite Warehouse Disruptions.

Clicks delivered firm interim results with diluted HEPS up 8.1%, even as warehouse system delays cost an estimated R175 million in lost sales. CEO Bertina Engelbrecht discusses pharmacy growth, trading margins, and festive‑season competition.
23 Apr 2PM 16 min